English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

With coronavirus infection, gastrointestinal manifestations with diarrhea, vomiting and abdominal pain are often noted. This is due to the susceptibility of the intestinal epithelium to the virus due to the expression of ACE2 receptors. In addition, elevated liver enzymes may occur in patients with COVID-19. Presumably, this can be caused both by direct damage to the liver with damage to SARS-CoV-2 hepatocytes, and by the development of pathological immune mechanisms or hepatotoxicity of drugs. In the event of gastrointestinal symptoms and an increase in hepatic transaminases, it seems appropriate to use modern enterosorbents in the complex therapy of coronavirus infection caused by COVID-19, such as polymethylsiloxane polyhydrate. Given the mechanisms of action of this drug, its use can contribute to a more rapid relief of diarrhea, a decrease in intoxication syndrome and normalization of transaminases

To the Issue of Intoxication and Diarrhea Syndrome Treatment in the Case of Coronavirus Infection